Skip to main content

Market Overview

Autolus Therapeutics Raises $100M Via Equity

  • Autolus Therapeutics PLC (NASDAQ: AUTLprices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.
  • The offering is expected to close on February 12.
  • J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering.
  • Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022.
  • Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development.
  • Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday.

Related Articles (AUTL)

View Comments and Join the Discussion!

Posted-In: acute lymphoblastic leukemiaBiotech News Offerings Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at